News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

CoreValve, Inc. Announces That More Than 1,800 High-Risk Patients Have Been Treated with its ReValvingĀ® System for Percutaneous Aortic Valve Replacement (PAVR)



10/13/2008 12:13:44 PM

IRVINE, Calif.--(BUSINESS WIRE)--CoreValve (www.corevalve.com) announced today that the expanded clinical evaluation of its ReValvingĀ® System for percutaneous aortic valve replacement (PAVR) in high-risk patients with aortic stenosis continues to enroll patients at an accelerating pace. More than 1,800 patients have now been treated worldwide at nearly 100 centers in 20 countries.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES